Skip to content
Peptigraph home

KPV

Anti-inflammatory tripeptide. KPV is not FDA approved for any use.

Also called:Lys-Pro-Valalpha-MSH fragment
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Animal evidence, 2 of 4
StatusPCAC voted 8–6 for 503A (Jul 2026)Removed from FDA Category 2 on 15 Apr 2026. PCAC voted 8–6 for the 503A list (Jul 2026); not finalized.WADA status unclearFull legal history

Key facts

Class
Anti-inflammatory tripeptide
Also called
Lys-Pro-Val, alpha-MSH fragment
Vial sizes sold
5 mg, 10 mg, 20 mg
Community-reported sizes
Half-life
Not found
No published half-life found (PubMed search, 11 Oct 2026)
FDA status
Not approved
Off Category 2, 15 Apr 2026
PCAC vote
8–6 for 503A
Jul 2026, not final
WADA
Unclear
Not named on the 2026 list
Everything on KPV

KPV guides

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

KPV: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Inflammation10196Animal evidence, 2 of 4Inflammatory bowel diseases 2008, PMID 18092346
Gut health462Animal evidence, 2 of 4Inflammatory bowel diseases 2008, PMID 18092346
Skin113In vitro evidence, 1 of 4Tissue & cell 2025, PMID 40073467

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

A three-amino-acid slice of alpha-MSH

KPV is the three-amino-acid fragment of alpha-MSH at positions 11 to 13.[6]

Mouse work found its anti-inflammatory effect is clearly different from that of the core MSH peptides.[15]

All of the evidence is animal or cell work

In mice with DSS colitis, KPV led to earlier recovery and weight regain, and in mice with a nonfunctional MC1 receptor it rescued all treated animals from death. This is animal data only.[6]

Oral KPV in drinking water reduced the incidence of DSS- and TNBS-induced colitis in mice.[16]

In ex vivo human skin, KPV permeation by simple passive diffusion was below the detection limit, which matters for cream and patch claims.[17]

The only stability study found reports that KPV degrades mainly to lys-pro-diketopiperazine under acid, alkali and peroxide stress.[18]

Regulatory path

Drugs@FDA has no KPV product.[4]

FDA removed KPV from category 2 because its nomination was withdrawn, and announced a PCAC consultation for July 23, 2026.[5]

Compared with

Common stacks

KPV is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.

KLOWGHK-Cu, BPC-157, TB-500 and KPV80 mg blendsBlend calculator
KPV + BPC-157KPV + GHK-Cu

Common questions

Is KPV FDA approved?

No. KPV is not FDA approved for any use. The FDA removed it from Category 2 on 15 Apr 2026. Its advisory committee voted 8–6 in July 2026 to add it to the 503A compounding list. That vote is not final.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

What is KPV?

A tripeptide, Lys-Pro-Val, corresponding to residues 11 to 13 of alpha-MSH.[6]

What does KPV do?

In mouse colitis models it improved recovery. No human trial was found.[6]

Is oral KPV or KPV in capsules studied?

Only in mice, where it was given in drinking water; no human oral study was found.[16]

Is there a KPV human clinical trial on ClinicalTrials.gov?

No. A ClinicalTrials.gov search for KPV or Lys-Pro-Val run on 2026-10-25 returned 0 registered studies.[19]

Sources

  1. 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  2. 2Pharmacy Compounding Advisory Committee meeting, 23–24 Jul 2026 (agenda and materials)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  3. 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  4. 4United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "KPV" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  5. 5US compounding: KPV was removed from FDA's 503A category 2 after the nominator withdrew; FDA announced a PCAC consultation on 23 July 2026.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  6. 6Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
  7. 7Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.Tissue & cell · 2025PMID 40073467Accessed 2 Oct 2026
  8. 8PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) (132 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (alpha-MSH[tiab] OR melanocortin[tiab] OR colitis[tiab] OR inflammat*[tiab]) (95 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (clinical trial[pt] OR randomized[tiab] OR patients[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
  13. 13FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  14. 14PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  15. 15Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.The Journal of pharmacology and experimental therapeutics · 2003PMID 12750433Accessed 2 Oct 2026
  16. 16PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.Gastroenterology · 2008PMID 18061177Accessed 2 Oct 2026
  17. 17Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.Journal of pharmaceutical sciences · 2017PMID 28343991Accessed 2 Oct 2026
  18. 18Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates.Biomedical chromatography : BMC · 2015PMID 25298219Accessed 2 Oct 2026
  19. 19clinicaltrials.gov: term KPV OR "Lys-Pro-Val"ClinicalTrials.gov · 2026clinicaltrials.govAccessed 25 Oct 2026

Found an error? Report a correction.